Table 6.
Reduction in Pharmacologic Glaucoma Medication – Summary of Studies
Study | No. of IOP-Lowering Agents at Baseline | No. of IOP-Lowering Agents 12 Months Postop | N | Glaucoma Type | Procedurea |
---|---|---|---|---|---|
De Gregorio et al,15 2018 | 2.5 | 0.4 | 41 | Mixed cases | Combined |
Gillmann et al,10 2019 | 1.9 2.0 |
0.6 0.4 |
110 | POAG PEXG |
Stand-alone and combined |
Grover et al,7 2017 | 3.5 | 1.7 | 65 | Mixed cases | Stand-alone |
Hengerer et al,16 2017 | 3.13 | 0.3 | 242 | Mixed cases | Stand-alone and combined |
Mansouri et al,9 2018 | 1.9 2.0 |
0.4 0.5 |
110 | POAG PEXG |
Stand-alone and combined |
Tan et al,12 2018 | 3.0 | 0.7 | 39 | Mixed cases | Stand-alone |
Widder et al,17 2018 | 2.6 | 0.2 | 233 | Mixed cases | Stand-alone and combined |
Notes: aStand-alone XEN procedure and/or XEN procedure combined with cataract surgery.
Abbreviations: IOP, intraocular pressure; POAG, primary open angle glaucoma; PEXG, pseudoexfoliative glaucoma.